Key result
Total myocardial scar mass and border zone mass independently predicted appropriate ICD therapy in patients with ischemic cardiomyopathy.
Why the study?
ICD therapy has deleterious effects that antiarrhythmic drugs or catheter ablation can reduce, but it is largely unknown which patients might benefit, prompting evaluation of whether myocardial scar characterization improves risk stratification for ventricular arrhythmias.
Does LGE-CMR-based myocardial scar characterization predict appropriate ICD therapy in patients with ischemic cardiomyopathy?
Observational (n=82)
No
Does LGE-CMR-based myocardial scar characterization predict appropriate ICD therapy in patients with ischemic cardiomyopathy?
LGE-CMR-based quantification of total scar and border zone mass, but not ECG characteristics, independently predicts the occurrence of ventricular arrhythmias requiring appropriate ICD therapy in patients with ischemic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Scar characterization may aid VA risk stratification in ischemic cardiomyopathy ICD patients; leaves open whether it should guide therapy selection.
Background: Implantable cardioverter-defibrillator (ICD) therapy is associated with several deleterious effects, which can be reduced by antiarrhythmic drugs or catheter ablation. However, it is largely unknown which patients might benefit from these therapies. Therefore, this study aimed to investigate whether myocardial scar characterization improves risk stratification for ventricular arrhythmia (VA) occurrence in patients with ischemic cardiomyopathy and an ICD. Methods: In this study, 82 patients with ischemic cardiomyopathy who received an ICD were enrolled retrospectively. Late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) images were analyzed using an investigational software tool to obtain quantitative data regarding the total scar, core, and border zone (BZ). Data regarding the QRS complex was obtained from electrocardiography (ECG). The primary endpoint was appropriate ICD therapy. Results: During a median follow-up duration of 3.98 years [interquartile range (IQR) 2.89–5.14 years], appropriate therapy occurred in 24 (29.3%) patients. Patients with appropriate ICD therapy had a significantly larger total scar mass [60.0 (IQR 41.2–73.4) vs. 43.3 (IQR 31.2–61.2) g; P = 0.009] and BZ mass [32.9 (IQR 26.9–42.4) vs. 24.5 (IQR 18.8–32.5) g; P = 0.001] than those without appropriate therapy. In multivariable Cox regression analyses, total scar mass [hazard ratio (HR) 1.02 [95% confidence interval (CI) 1.00–1.04]; P = 0.014] and BZ mass (HR 1.04 [95% CI 1.01–1.07]; P = 0.009) independently predicted appropriate ICD therapy. Core mass and the QRS complex, however, were not significantly associated with the primary endpoint. Conclusion: LGE-CMR-based, but not ECG-based myocardial scar characterization improves risk stratification for VA occurrence in patients with ischemic cardiomyopathy who received an ICD.
No takes yet. Share an insight, caveat, or question.
Noordman et al. (2021) conducted an observational in Ischemic cardiomyopathy (n=82). Total myocardial scar mass was evaluated on Appropriate ICD therapy (HR 1.02, 95% CI 1.00-1.04, p=0.014). Total myocardial scar mass and border zone mass independently predicted appropriate ICD therapy in patients with ischemic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: